İsmail Hakkı Akbeyaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
İsmail Hakkı Akbeyaz has a total of 228 co-authors. Here are the top co-authors by number of shared publications:
- Dilşad Türkdoğan
Department of Pediatric Neurology, Marmara University Faculty of Medicine, Pendik Training and Research Hospital, Istanbul, Türkiye
4 shared publications - Olcay Ünver
Environmental and Resource Management Program, Fulton Schools of Engineering, Arizona State University, Tempe, AZ 85287-9309, USA
4 shared publications - Ayten Güleç
Department of Pediatrics, Division of Pediatric Neurology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
2 shared publications - Bahadır Konuşkan
Department of Pediatric Neurology, Ankara Etlik City Hospital, Ankara, Turkiye
2 shared publications - Bilge Özgör
Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, İnönü University, Malatya 44050, Türkiye
2 shared publications - Burcu Karakayalı
Marmara University Training and Research Hospital, Department of Pediatric Neurology, Istanbul, Turkey
2 shared publications
Latest Publications
- 7 March 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 179, 110982
Extreme ambient temperatures and seizure outcomes in children with epilepsy: insights from a survey in Turkey
- 7 March 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 179, 110982
Extreme ambient temperatures and seizure outcomes in children with epilepsy: insights from a survey in Turkey
- Open Access
Personalized Management and Timing of Thymectomy in Juvenile Myasthenia Gravis: Insights from Routine Clinical Scale Use in a Single-Center Retrospective Cohort—A Case Series
Introduction: Juvenile myasthenia gravis (JMG) is a rare autoimmune disorder with a variable clinical course and limited pediatric-specific treatment guidelines. Objective clinical scales, such as the Quantitative Myasthenia Gravis (QMG) Score and the Pediatric Myasthenia Gravis Quality of Life 15 (PM-QOL15), may support individualized management, but their role in routine practice remains underexplored. Methods: We retrospectively reviewed 10 seropositive JMG patients followed at a single tertiary neuromuscular clinic between 2014 and 2024. All patients underwent a systematic assessment with QMG at each visit, while PM-QOL15 was administered at the final visit. Clinical data, comorbidities, antibody status, treatment modalities, and outcomes were analyzed. Associations between treatment strategies, comorbidities, and scale scores were explored using appropriate statistical methods. Results: Seven patients (70%) underwent thymectomy, resulting in a reduction in mean QMG scores from 7.7 to 2.4, though residual relapses were observed. Chronic intravenous immunoglobulin (IVIG) therapy, administered to 70% of patients, did not significantly reduce relapse rates or steroid exposure and was associated with higher QMG scores in the second year, suggesting use in more severe phenotypes rather than therapeutic efficacy. Prolonged corticosteroid therapy did not improve remission time or relapse frequency and was complicated by major adverse effects in two patients. Timing of azathioprine initiation showed no significant correlation with relapse frequency. PM-QOL15 correlated strongly with mean QMG (r = 0.88, p < 0.001), reflecting cumulative disease burden. Patients with comorbidities required longer stabilization, although differences were not statistically significant. Conclusions: The routine integration of QMG and PM-QOL15 into follow-up may facilitate the earlier recognition of subclinical deterioration, provide objective measures of treatment response, and guide personalized management in JMG. Thymectomy showed benefit in selected patients, while the long-term roles of IVIG and corticosteroids remain uncertain. Larger multicenter prospective studies are warranted to confirm these findings and refine evidence-based strategies for pediatric JMG.
Open AccessPersonalized Management and Timing of Thymectomy in Juvenile Myasthenia Gravis: Insights from Routine Clinical Scale Use in a Single-Center Retrospective Cohort—A Case Series
Introduction: Juvenile myasthenia gravis (JMG) is a rare autoimmune disorder with a variable clinical course and limited pediatric-specific treatment guidelines. Objective clinical scales, such as the Quantitative Myasthenia Gravis (QMG) Score and the Pediatric Myasthenia Gravis Quality of Life 15 (PM-QOL15), may support individualized management, but their role in routine practice remains underexplored. Methods: We retrospectively reviewed 10 seropositive JMG patients followed at a single tertiary neuromuscular clinic between 2014 and 2024. All patients underwent a systematic assessment with QMG at each visit, while PM-QOL15 was administered at the final visit. Clinical data, comorbidities, antibody status, treatment modalities, and outcomes were analyzed. Associations between treatment strategies, comorbidities, and scale scores were explored using appropriate statistical methods. Results: Seven patients (70%) underwent thymectomy, resulting in a reduction in mean QMG scores from 7.7 to 2.4, though residual relapses were observed. Chronic intravenous immunoglobulin (IVIG) therapy, administered to 70% of patients, did not significantly reduce relapse rates or steroid exposure and was associated with higher QMG scores in the second year, suggesting use in more severe phenotypes rather than therapeutic efficacy. Prolonged corticosteroid therapy did not improve remission time or relapse frequency and was complicated by major adverse effects in two patients. Timing of azathioprine initiation showed no significant correlation with relapse frequency. PM-QOL15 correlated strongly with mean QMG (r = 0.88, p < 0.001), reflecting cumulative disease burden. Patients with comorbidities required longer stabilization, although differences were not statistically significant. Conclusions: The routine integration of QMG and PM-QOL15 into follow-up may facilitate the earlier recognition of subclinical deterioration, provide objective measures of treatment response, and guide personalized management in JMG. Thymectomy showed benefit in selected patients, while the long-term roles of IVIG and corticosteroids remain uncertain. Larger multicenter prospective studies are warranted to confirm these findings and refine evidence-based strategies for pediatric JMG.
- Open Access
- 1 September 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (5) , 546-551
Kohlschütter-Tönz Syndrome: A Rare Clinical Entity with Amelogenesis Imperfecta in Two Siblings, Dental Management and Scoping Review
Kohlschütter-Tönz syndrome (KTS) (OMIM#226750) is a rare autosomal recessive disorder characterized by epileptic encephalopathy, developmental delay, and amelogenesis imperfecta. Early diagnosis and management are crucial, but the complexity of symptoms, particularly dental and neurological impairments, poses significant challenges. The aim of this report is to describe the clinical findings of 2 siblings and their dental management, whose dental examination led to genetic referral and subsequent diagnosis of KTS. Dental examinations revealed enamel defects consistent with amelogenesis imperfecta, including yellow-brown discoloration, soft enamel, and diastemas in both siblings. The younger sibling, a 9-year-old boy, exhibited early-onset seizures, intellectual disability, spasticity, and a history of kidney stones. The older sibling, a 13-year-old boy, presented with more severe neurodevelopmental delay, early-onset seizures, and drug-resistant epilepsy. Genetic testing confirmed homozygous deletions in the ROGDI gene, leading to the diagnosis of KTS in both siblings. The younger sibling received successful restorative treatment under general anesthesia, while the older sibling’s oral care was managed conservatively due to contraindications for general anesthesia. These cases underscore the importance of pediatric dentists in the early identification of rare genetic disorders such as KTS, especially when dental anomalies like amelogenesis imperfecta are present. Timely referral for genetic evaluation can facilitate accurate diagnosis and appropriate care planning. Moreover, sharing clinical experiences and treatment outcomes contributes to a better understanding of this rare syndrome and helps guide future diagnostic and therapeutic strategies. Cite this article as: Akbeyaz Şivet E, Akbeyaz İH, Berkel G, Yeşilyurt A, Sezer B, Menteş A. KohlschütterTönz syndrome: A rare clinical entity with amelogenesis imperfecta in two siblings, dental management and scoping review. Turk Arch Pediatr. 2025;60(5):546-551.
- 1 September 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (5) , 546-551
Open AccessKohlschütter-Tönz Syndrome: A Rare Clinical Entity with Amelogenesis Imperfecta in Two Siblings, Dental Management and Scoping Review
Kohlschütter-Tönz syndrome (KTS) (OMIM#226750) is a rare autosomal recessive disorder characterized by epileptic encephalopathy, developmental delay, and amelogenesis imperfecta. Early diagnosis and management are crucial, but the complexity of symptoms, particularly dental and neurological impairments, poses significant challenges. The aim of this report is to describe the clinical findings of 2 siblings and their dental management, whose dental examination led to genetic referral and subsequent diagnosis of KTS. Dental examinations revealed enamel defects consistent with amelogenesis imperfecta, including yellow-brown discoloration, soft enamel, and diastemas in both siblings. The younger sibling, a 9-year-old boy, exhibited early-onset seizures, intellectual disability, spasticity, and a history of kidney stones. The older sibling, a 13-year-old boy, presented with more severe neurodevelopmental delay, early-onset seizures, and drug-resistant epilepsy. Genetic testing confirmed homozygous deletions in the ROGDI gene, leading to the diagnosis of KTS in both siblings. The younger sibling received successful restorative treatment under general anesthesia, while the older sibling’s oral care was managed conservatively due to contraindications for general anesthesia. These cases underscore the importance of pediatric dentists in the early identification of rare genetic disorders such as KTS, especially when dental anomalies like amelogenesis imperfecta are present. Timely referral for genetic evaluation can facilitate accurate diagnosis and appropriate care planning. Moreover, sharing clinical experiences and treatment outcomes contributes to a better understanding of this rare syndrome and helps guide future diagnostic and therapeutic strategies. Cite this article as: Akbeyaz Şivet E, Akbeyaz İH, Berkel G, Yeşilyurt A, Sezer B, Menteş A. KohlschütterTönz syndrome: A rare clinical entity with amelogenesis imperfecta in two siblings, dental management and scoping review. Turk Arch Pediatr. 2025;60(5):546-551.
- 29 April 2025
- Published by Academician Publishing
- p. 733-734
DNA Tamir Bozuklukları ve Görüntüleme Bulguları
- 29 April 2025
- Published by Academician Publishing
- p. 733-734
DNA Tamir Bozuklukları ve Görüntüleme Bulguları
- Open Access
- 29 April 2025
- Published by Academician Publishing
Canpolat&Karaman&Kardaş - Temel Pediatrik Nöroradyoloji Nörometabolik ve Heredodejeneratif Hastalıklarda Klinik ve Radyolojik Yaklaşım
- 29 April 2025
- Published by Academician Publishing
Open AccessCanpolat&Karaman&Kardaş - Temel Pediatrik Nöroradyoloji Nörometabolik ve Heredodejeneratif Hastalıklarda Klinik ve Radyolojik Yaklaşım
- 17 December 2024
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 38 (2) , 196-200
Unclear symptoms, early diagnosis and perfect outcome: a case diagnosed as sepiapterin reductase deficiency hidden behind vitamin B12 deficiency
Objectives: Sepiapterin reductase deficiency (SRD) is a rare dopa-sensitive neurotransmitter disorder caused by autosomal recessive mutations in the sepiapterin reductase gene. The triad of paroxysmal stiffening, oculogyric crises, and hypotonia are highly suggestive in some patients. However, in other patients, the clinical picture may be nonspecific and remain under-recognized and misdiagnosed as cerebral palsy. Case presentation: We present a nine-month-old boy who initially presented with hypotonia and developmental delay, diagnosed as vitamin B12 deficiency. Upon he did not respond to vitamin replacement treatment, he was diagnosed with SRD by whole-exome sequencing (WES). The boy improved dramatically under treatment with L-dopa, 5-hydroxytryptophan and BH4. Conclusions: We aim to emphasize that SRD can present with nonspecific symptoms, leading to a diagnostic delay for this rare but treatable disease. Moreover, our case is the first to demonstrate the clinical benefit of BH4 add-on treatment. Early intervention is crucial for good outcome and neurodevelopment.
- 17 December 2024
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 38 (2) , 196-200
Unclear symptoms, early diagnosis and perfect outcome: a case diagnosed as sepiapterin reductase deficiency hidden behind vitamin B12 deficiency
Objectives: Sepiapterin reductase deficiency (SRD) is a rare dopa-sensitive neurotransmitter disorder caused by autosomal recessive mutations in the sepiapterin reductase gene. The triad of paroxysmal stiffening, oculogyric crises, and hypotonia are highly suggestive in some patients. However, in other patients, the clinical picture may be nonspecific and remain under-recognized and misdiagnosed as cerebral palsy. Case presentation: We present a nine-month-old boy who initially presented with hypotonia and developmental delay, diagnosed as vitamin B12 deficiency. Upon he did not respond to vitamin replacement treatment, he was diagnosed with SRD by whole-exome sequencing (WES). The boy improved dramatically under treatment with L-dopa, 5-hydroxytryptophan and BH4. Conclusions: We aim to emphasize that SRD can present with nonspecific symptoms, leading to a diagnostic delay for this rare but treatable disease. Moreover, our case is the first to demonstrate the clinical benefit of BH4 add-on treatment. Early intervention is crucial for good outcome and neurodevelopment.
- 21 September 2024
- Published by Academician Publishing
- p. 443-450
Epilepside Tanısal Yaklaşım
Yeni teşhis edilen epilepside çocuklar ve yaşlılar en sık görülen yaş gruplarıdır. Epileptik olmayan “nöbet” terimi, epileptik nöbetlere benzeyen ancak farklı nedenlere sahip paroksismal olayları tanımlamak için kullanılmaktadır. Örneğin Psikojenik nöbetler, altta yatan çeşitli psikolojik sorunlardan kaynaklanan ve tekrarlayan, epileptik nöbetleri taklit eden paroksizmal olaylardır. Epileptik nöbetlerde EEG’nin her zaman anormal olmaması ya da EEG kaydının kas ve hareket artefaktları ile örtülü olması da tanısal süreçte yaşanan zorluklardandır. In newly diagnosed epilepsy, children and the elderly are the most common age groups. The term "nonepileptic seizure" is used to describe paroxysmal events that resemble epileptic seizures but have different underlying causes. For example, psychogenic seizures are paroxysmal events that mimic epileptic seizures and occur due to various underlying psychological issues. One of the diagnostic challenges in epileptic seizures is that the EEG is not always abnormal, or the EEG recording may be obscured by muscle and movement artifacts.
- 21 September 2024
- Published by Academician Publishing
- p. 443-450
Epilepside Tanısal Yaklaşım
Yeni teşhis edilen epilepside çocuklar ve yaşlılar en sık görülen yaş gruplarıdır. Epileptik olmayan “nöbet” terimi, epileptik nöbetlere benzeyen ancak farklı nedenlere sahip paroksismal olayları tanımlamak için kullanılmaktadır. Örneğin Psikojenik nöbetler, altta yatan çeşitli psikolojik sorunlardan kaynaklanan ve tekrarlayan, epileptik nöbetleri taklit eden paroksizmal olaylardır. Epileptik nöbetlerde EEG’nin her zaman anormal olmaması ya da EEG kaydının kas ve hareket artefaktları ile örtülü olması da tanısal süreçte yaşanan zorluklardandır. In newly diagnosed epilepsy, children and the elderly are the most common age groups. The term "nonepileptic seizure" is used to describe paroxysmal events that resemble epileptic seizures but have different underlying causes. For example, psychogenic seizures are paroxysmal events that mimic epileptic seizures and occur due to various underlying psychological issues. One of the diagnostic challenges in epileptic seizures is that the EEG is not always abnormal, or the EEG recording may be obscured by muscle and movement artifacts.